文献速递瓣膜外科

术前β受体阻滞剂与主动脉瓣置换术后更差结局相关

Preoperative β-blocker use correlates with worse outcomes in patients undergoing aortic valve replacement.
PubMed 文献 · J Thorac Cardiovasc Surg · 2019-02-13

该多中心州级数据库 propensity 匹配研究纳入 2002–2016 年 7380 例孤立主动脉瓣置换患者,53% 术前使用β受体阻滞剂。匹配后 4592 例基线均衡,两组手术死亡率和主要并发症率相似,但β阻滞组心脏骤停、透析依赖肾衰、输血和术后房颤更多,ICU 停留更长。结论不支持常规术前启用β阻滞剂。

要点

  • 术前β阻滞未改善主动脉瓣置换术后死亡率或主要并发症。
  • β阻滞组心脏骤停、透析肾衰、输血和术后房颤发生率更高。
  • 不应在主动脉瓣置换术前常规启用β受体阻滞剂。

核心结论

  • 术前β受体阻滞剂与主动脉瓣置换术后结局改善无关,反而与术后并发症增加相关。
  • 对主动脉瓣置换患者常规术前启用β受体阻滞剂缺乏支持。

研究设计与样本

  • 回顾性多中心州级数据库研究,提取 2002–2016 年孤立主动脉瓣置换患者。
  • 7380 例符合条件患者中 53% 接受术前β受体阻滞剂,倾向评分匹配后 4592 例 1:1 配对。

主要发现

  • 匹配队列中手术死亡率β阻滞组 2.8% 对无β阻滞组 2.4%(P = .454),主要并发症率 14.4% 对 12.7%(P = .101)。
  • 心脏骤停发生率 2.1% 对 1.3%(P = .034),透析依赖肾衰 1.7% 对 0.9%(P = .007),术后输血 38.2% 对 33.8%(P = .002)。
  • 术后房颤 26.9% 对 23.4%(P = .007),术前β阻滞组 ICU 停留更长(45.2 对 47.0 小时,P = .001)。

临床怎么用

  • 主动脉瓣置换术前不应常规启动β受体阻滞剂以改善结局。
  • 对已使用β阻滞剂者需权衡术后心脏骤停、肾衰、输血和房颤风险。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: β-Blocker use is associated with fewer cardiac complications in patients undergoing noncardiac surgery and is a quality metric for coronary artery bypass grafting. We sought to determine the influence of preoperative β-blocker administration before aortic valve replacement (AVR). METHODS: All patients undergoing isolated AVR from 2002 to 2016 were extracted from a multi-institutional, statewide database composed of Society of Thoracic Surgeons data. Patients were propensity score matched by preoperative and operative variables, and the effects of preoperative β-blockers on outcomes were assessed. RESULTS: Of 7380 eligible patients, 53% received a preoperative β-blocker. After propensity matching, a total of 4592 patients were well matched (1:1) with minimal baseline differences between groups. Within the matched cohort, the operative mortality rate (β-blocker: 2.8% vs no β-blocker: 2.4%; P = .454) and rate of major morbidity (14.4% vs 12.7%; P = .101) were similar between groups. The rates of cardiac arrest (2.1% vs 1.3%; P = .034), renal failure requiring dialysis (1.7% vs 0.9%; P = .007), and postoperative transfusion (38.2% vs 33.8%; P = .002) after AVR were significantly greater in the cohort receiving preoperative β-blockade. Postoperative atrial fibrillation was also more prevalent in patients receiving a preoperative β-blocker (26.9% vs 23.4%; P = .007). Finally, preoperative β-blocker use was associated with longer postoperative intensive care unit stays (45.2 vs 47.0 hours; P = .001), but clinically similar hospital length of stay. CONCLUSIONS: Preoperative β-blocker administration is not associated with improved outcomes after AVR but instead is associated with increased postoperative morbidity. Routinely initiating preoperative β-blockade is not supported in patients undergoing AVR.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Schubert SA, Hawkins RB, Mehaffey JH, et al. Preoperative β-blocker use correlates with worse outcomes in patients undergoing aortic valve replacement. J Thorac Cardiovasc Surg. 2019. PMID: 30928218. doi:10.1016/j.jtcvs.2018.12.108

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。